Multiple myeloma (MM) is a type of white blood cell cancer and an incurable disease. This disease accounts for about 20% of deaths caused by hematological malignancies. It can become resistant to chemotherapies and may result into to deaths. To cure MM, there is a need to discover early biomarkers of bad prognosis of MM and novel therapeutic targets. By using single cell RNA sequencing (scRNASeq) and bulk-RNASeq promising targets of bad MM prognosis and novel therapeutic targets can be found. Primerly, we will perform the sequencing on cell lines (No patient materials) and they will be integrated with already published online data for robust discoveries. For this purpose we already have access to cell lines those are resistant to well known MM therapies likes lenalidomide and bortezomib while they are diverse genetic background.